Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer

Inclusion: * Recurrent and/or metastatic resectable colorectal cancer, including disease within the abdomen and pelvis with no evidence of extra-abdominal metastases. Isolated resectable pulmonary metastasis are allowable in the absence of intra-abdominal metastasis. Intra-abdominal disease includes: isolated hepatic metastasis/metastases (see next inclusion criteria point), isolated peritoneal metastasis, peritoneal carcinomatosis (including patients undergoing cytoreductive surgery alone or in combination with hyperthermic intraperitoneal chemoperfusion - HIPEC), or a combination of hepatic and extrahepatic metastasis. * Patients with isolated hepatic metastasis must satisfy a Clinical Risk Score of 3 or higher (see Appendix C) * Eligible patients are expected to have a complete resection based on preoperative imaging. Any patient not found to be able to have complete resection will not be eligible for this study. * No chemotherapy, radiotherapy, major surgery, or biologic therapy within 3 weeks of protocol treatment * An ECOG performance status of 0, 1, or 2. * Age equal to 18 years or older. * Must have normal organ and marrow function as defined below: * Platelet ≥ 75,000/µL * Hemoglobin ≥ 9.0 g/dL * Hematocrit ≥ 27.0% * Absolute Neutrophil Count (ANC) ≥ 1500/µL * Creatinine \< institutional upper limit of normal (ULN) OR * Creatinine clearance ≥ 50 mL/min/1.73 m2 for patients with creatinine levels greater than ULN * Total bilirubin ≤ 1.5 X institutional upper limit of normal (ULN) * AST(SGOT) and ALT(SGPT) ≤ 2.5 X institutional upper limit of normal (ULN) * Serum amylase and lipase within normal limits. * Patient must be able to understand and be willing to sign a written informed consent document. Exclusion: * Patients currently treated with systemic immunosuppressive agents, including steroids, are ineligible until 3 weeks after removal from immunosuppressive treatment. * Patients with active autoimmune disease or history of transplantation. * Patients who are pregnant or nursing. Women of childbearing potential (WOCBP) will have to undergo a urine pregnancy test as part of screening. * Patients with comorbid medical conditions that render them unfit for surgery. * Metastatic or recurrent disease that is deemed partially resectable or unresectable based on preoperative imaging. * Metastatic disease outside the confines of the abdomen, pelvis and thorax (e.g bone, brain) * Cardiac risk factors including: * Patients experiencing cardiac event(s) (acute coronary syndrome, myocardial infarction, or ischemia) within 3 months of signing consent * Patients with a New York Heart Association classification of III or IV (Appendix A) * History of upper gastrointestinal ulceration, upper gastrointestinal bleeding, or upper gastrointestinal perforation within the past 3 years. Patients with ulceration, bleeding or perforation in the lower bowel are not excluded. * Prior allergic reaction or hypersensitivity to sulfonamides, celecoxib, or NSAIDs. * Patients are ineligible if they plan on regular use of NSAIDs at any dose more than 2 times per week (on average) or aspirin at more than 325 mg at least three times per week, on average. Low-dose aspirin not exceeding 100 mg/day is permitted. Patients who agree to stop regular NSAIDs or higher dose aspirin are eligible and no wash out period is required.